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We describe a case of treatment failure caused by a
strain of USA300 community-associated methicillin-resist-
ant Staphylococcus aureus (MRSA) with intermediate sus-
ceptibility to vancomycin and reduced susceptibility to
daptomycin. The strain was isolated from the bone of a 56-
year-old man with lumbar osteomyelitis after a 6-week
treatment course of vancomycin for catheter-associated
septic thrombophlebitis.
A56-year-old man with a history of type 2 diabetes andchronic kidney disease was seen at San Francisco
General Hospital in November 2005 because of hyper-
kalemia and volume overload. On day 4 of hospitalization,
a fever of 39°C and cellulitis in the right arm associated
with a peripheral intravenous line developed. Two blood
cultures were drawn, the line was removed, and therapy
was initiated with oral cephalexin. One of the 2 blood cul-
tures subsequently grew methicillin-resistant Staphylo-
coccus aureus (MRSA) that was susceptible to tetracycline
and trimethoprim-sulfamethoxazole. The patient was treat-
ed with oral trimethoprim-sulfamethoxazole and dis-
charged to home to complete a 10-day course. His right
upper extremity cellulitis subsequently resolved, but he
returned to the hospital in January 2006 with volume over-
load and symptoms consistent with uremia. A tunneled
right internal jugular hemodialysis catheter was placed on
January 11, hemodialysis was initiated, and he was dis-
charged to home.
On February 20, he was seen in the emergency depart-
ment of another facility with nausea and altered mental sta-
tus. He was afebrile but hypotensive, and tenderness at the
entrance site of the hemodialysis catheter was noted. Two
blood cultures were positive for MRSA. The patient’s
catheter was removed, and intravenous vancomycin was
started. Transthoracic and subsequent transesophageal
echocardiograms were negative for endocarditis, but evi-
dence of thrombosis in the superior vena cava was seen.
Multiple blood cultures were positive for MRSA through
March 1, after which they became negative. The van-
comycin MIC for serial isolates remained unchanged. The
patient was treated with vancomycin for a 6-week course,
beginning March 1. Anticoagulation with coumadin was
also initiated. After clearance of his blood cultures, a right
subclavian tunneled hemodialysis catheter and a left upper
extremity arteriovenous fistula were placed. Vancomycin
trough levels were assayed on multiple occasions during
the 6-week course; all were >20 µg/mL.
On April 24, the patient was seen by his primary care
provider for worsening bilateral knee and back pain and
difficulty walking. A lumbar spine radiograph demonstrat-
ed cortical irregularity at L4-L5, indicative of discitis. He
was admitted to the hospital, and vancomycin was initiat-
ed. Magnetic resonance imaging of the lumbar spine on
April 25 demonstrated findings consistent with
osteomyelitis and discitis at L4-L5. A needle biopsy of the
L4-L5 lesion was performed on April 27. That evening, the
patient was noted to be febrile and had an episode of eme-
sis. Later in the evening, he was apneic and without a
pulse, with fixed and dilated pupils. Cardiopulmonary
resuscitation was performed. When neurologic function
did not return during the next 4 days, supportive care was
withdrawn, and the patient died May 1. Multiple blood cul-
tures from this hospitalization remained negative, but
results of a culture of lumbar fluid from a biopsy specimen
on April 27 were positive for a vancomycin-intermediate
S. aureus (VISA) isolate, with a vancomycin MIC of 8
µg/mL.
The antimicrobial susceptibility profiles of the blood
isolates from November and February and the lumbar iso-
late from April are shown in the Table. All MIC suscepti-
bilities were determined by broth microdilution methods
per Clinical and Laboratory Standards Institute guidelines.
The November and April isolates were tested with
MicroScan overnight panels (Dade Behring, Deerfield, IL,
USA); the February isolate was tested by using a noncom-
mercial tray. Confirmatory testing of the vancomycin MIC
of the April isolate was determined by E-test, which
returned an MIC of 6 µg/mL initially and 4 µg/mL on
repeat testing. The isolate also grew on vancomycin (6
µg/mL) agar screen plates. Susceptibilities to daptomycin,
linezolid, and tigecycline were performed on the February
and April isolates by E-test. Notably, the daptomycin MIC
of the April isolate was reproducibly 2 µg/mL, an increase
from 1 µg/mL for the February isolate. On blood agar
plate, the April lumbar isolate was noted to be weakly β-
hemolytic with small colony size. With multiple subcul-
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tures in the absence of vancomycin this morphotype
reverted to the full β-hemolysis and large colony size typ-
ical of S. aureus, intermediate susceptibility to van-
comycin was lost, and daptomycin susceptibility was
regained.
Pulsed-field gel electrophoresis with SmaI digestion
was performed on the 2 blood isolates from November and
February and the lumbar isolate from April. All 3 isolates
shared an identical pattern with the USA300-0114 control
strain (Figure). Sequencing of the protein A gene polymor-
phic region (spa typing) (1) of the lumbar isolate obtained
the sequence YHGFMBQBLO, typical for clonal cluster 8.
PCR was positive for the presence of mecA, ACME (argi-
nine catabolic mobile element, a signature gene cluster of
USA300), and Panton-Valentine leukocidin genes and neg-
ative for the presence of the vanA gene, when primers and
sequences previously described were used (2–4).
The community MRSA clone USA300, first identified
in 2001, has emerged as a notable cause of colonization
and disease in San Francisco (5). This clone has been
remarkable for its rapid spread and propensity to cause
severe infection, particularly skin and soft tissue and pul-
monary infection. Recent sequencing of its genome
demonstrated possible contributors to its virulence, most
notably Panton-Valentine leukocidin and ACME (2). The
USA300-0114 subclone has been the predominant one
during the community MRSA epidemic in San Francisco
(6) and is becoming widely prevalent in communities
throughout the United States (7). Surveys of clinical
MRSA isolates throughout the city of San Francisco have
shown an explosive increase in the prevalence of disease
caused by USA300 and displacement of other clones in
both inpatient and outpatient settings since 2001, blurring
the clone’s distinction as community associated.
The first report of clinical VISA infection was from
Japan in 1997 (8). Molecular typing of this and subsequent
VISA isolates showed these to be derived from prevalent
hospital-acquired clones primarily belonging to clonal
cluster 5 (9). The accessory gene regulator (agr) group II
genotype present in clonal cluster 5 strains has been spec-
ulated to predispose to emergence of the VISA phenotype.
USA300 is an agr group III clone (6). The occurrence of
the vancomycin-intermediate phenotype in USA300 sug-
gests that development of this phenotype may simply
reflect the prevalence of clones in a particular population,
rather than a causal relationship to agr.
The mechanism of reduced vancomycin susceptibility
in VISA is thought to be mediated by an increase in the
number of false targets because of a thickened cell wall
(10), perhaps aided by altered expression of penicillin-
binding proteins 2 and 4 (11). VISA and hVISA, strains of
S. aureus that contain subpopulations of daughter cells dis-
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Figure. Pulsed-field gel electrophoresis profiles of November and
February blood isolates (lanes 1 and 2), April lumbar isolate (lane
3), reference USA300-0114 isolate (lane 4), and internal control
g195a (lane 5).
playing intermediate sensitivity to vancomycin but for
which the MICs for vancomycin fall within the susceptible
range, can be difficult to detect in the microbiology labo-
ratory because the phenotypes are unstable and can be lost
on subsequent passages (12); this situation was demon-
strated in our case. Reduced susceptibility to daptomycin
in vancomycin-intermediate isolates has been described
previously, perhaps because of reduced diffusion of the
molecule through the thickened cell wall, although this has
not been proven (13). The clinical importance of the
reduced daptomycin susceptibility seen in vancomycin-
intermediate isolates, however, is unclear at this time.
Our patient experienced clinical failure of van-
comycin therapy despite high serum drug levels, which
speaks to the difficulty with which highly invasive S.
aureus infections are successfully treated with van-
comycin, particularly in patients receiving hemodialysis.
While most VISA isolates reported in the United States
have been isolated from patients receiving hemodialysis,
chronic renal disease and hemodialysis have not been
definitively identified as risk factors for infections caused
by VISA or hVISA (14). The frequency of nasal coloniza-
tion with hVISA was low in hemodialysis patients moni-
tored from 1999 to 2002 in the San Francisco Bay Area
(15). However, as the prevalence of USA300 increases and
prompts further use of vancomycin, intermediate van-
comycin susceptibility in USA300 may become more
common among both community and hospital isolates.
Dr Graber is a senior infectious diseases fellow at the
University of California, San Francisco. His research interests
include the molecular and clinical epidemiology of S. aureus
infection and its interaction with HIV disease.
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